Neurodegenerative disorders: Parkinson's disease and Huntington's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 8, 2005, Pages 1058-1063

  Hague, S M ^b   Klaffke, S ^b   Bandmann, Oliver ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CASPASE 8; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLOOXYGENASE 2; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HUNTINGTIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PARKIN; POLYGLUTAMINE;

CELL DEATH; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; LEWY BODY; MITOCHONDRIAL RESPIRATION; MOLECULAR GENETICS; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

AGED; AGED, 80 AND OVER; ALLELES; ANIMALS; GENE EXPRESSION; HUMANS; HUNTINGTON DISEASE; MICE; MICROGLIA; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOMICS; SYNUCLEINS; TRINUCLEOTIDE REPEATS; UBIQUITIN-PROTEIN LIGASES;

EID: 23144455501     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.060186     Document Type: Review

References (72)

1. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 2000;321:21-22.
2. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
3. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
4. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-73.
5. Kobayashi H, Kruger R, Markopoulou K, et al. Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. Brain 2003;126:32-42.
6. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40:767-75.
7. Spira PJ, Sharpe DM, Halliday G, et al. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 2001;49:313-19.
8. Kruger R, Kuhn W, Leenders KL, et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2000;56:1355-62.
9. Kruger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/ apolipoprotein E genotype. Ann Neurol 1999;45:611-17.
10. Khan N, Graham E, Dixon P, et al. Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype. Ann Neurol 2001;49:665-8.
11. Farrer M, Maraganore DM, Lockhart P, et al. Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-51.
12. Alves da Costa C. Recent advances on alpha-synuclein cell biology: functions and dysfunctions. Curr Mol Med 2003;3:17-24.
13. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Sny-Drager syndrome). J Neurol Sci 1989;94:79-100.
14. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-52.
15. Lansbury PT, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Cell Biol 2002;14:653-60.
16. Kirik D, Annett LE, Burger C, et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100:2884-9.
17. Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002;99:14524-9.
18. Souza JM, Giasson BI, Chen Q, et al. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000;275:18344-9.
19. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-6.
20. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
21. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-7.
22. Klein C, Pramstaller PP, Kis B, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000;48:65-71.
23. Khan NL, Brooks DJ, Pavese N, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002;125:2248-56.
24. Kuroda Y, Mitsui T, Akaike M, et al. Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism. J Neurol Neurosurg Psychiatry 2001;71:231-4.
25. West AB, Maraganore D, Crook J, et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum Mol Genet 2002;11:2787-92.
26. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-2.
27. Maraganore DM, Farrer AAJ, Hardy JA, et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999;53:1858-60.
28. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications. J Cell Biochem Suppl 2000;34:40-51.
29. Dawson TM, Dawson VL. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 2003;111:145-51.
30. Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001;21:9549-60.
31. McNaught KS, Belizaire R, Isacson O, et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38-46.
32. Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003;54:271-4.
33. Bonifati V, Breedveld GJ, Squitieri F, et al. Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol 2002;51:253-6.
34. Miller DW, Ahmad R, Hague S, et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 2003;278:36588-95.
35. Yokota T, Sugawara K, Ito K, et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 2003;312:1342-8.
36. Rizzu P, Hinkle DA, Zhukareva V, et al. DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia. Ann Neurol 2004;55:113-18.
37. Neumann M, Muller V, Gorner K, et al. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol (Berl) 2004;107:489-96.
38. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1158-60.
39. Rohe CF, Montagna P, Breedveld G, et al. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann Neurol 2004;56:427-31.
40. Maraganore DM, Wilkes K, Lesnick TH, et al. A limited role for DJ 1 in Parkinson disease susceptibility. Neurology 2004;63:550-3.
41. Healy DG, Abou-Sleiman PM, Ahmadi KR, et al. The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism. Ann Neurol 2004;56:329-35.
42. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease. Neuron 2004;44:595-600.
43. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. Neuron 2004;44:601-7.
44. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005;365:410-12.
45. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005;365:412-15.
46. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-16.
47. Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003;33:85-9.
48. McCormack AL, Thiruchelvam M, Manning-Bog AB, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002;10:119-27.
49. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6.
50. Hoglinger GU, Feger J, Prigent A, et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 2003;84:491-502.
51. Gao HM, Hong JS, Zhang W, et al. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 2003;23:1228-36.
52. Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002;68:325-40.
53. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-8.
54. McNaught KS, Pearl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-62.
55. McLean PJ, Kawamata H, Hyman BT. α-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001;104:901-12.
56. Auluck PK, Meulener MC, Bonini NM. Mechanisms of Suppression of alpha synuclein Neurotoxicity by Geldanamycin in Drosophila. J Biol Chem 2005;280:2873-8.
57. Farrer M, Maraganore DM, Lockhart P, et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-51.
58. Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther 2005;16:262-70.
59. Temussi PA, Masino L, Pastore A. From Alzheimer to Huntington: why is a structural understanding so difficult? Embo J 2003;11:355-61.
60. Squitieri F, Gellera C, Cannella M, et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003;126:946-55.
61. Ross CA, Poirier MA, Wanker EE, et al. Polyglutamine fibrillogenesis: the pathway unfolds. Proc Natl Acad Sci USA 2003;100:1-3.
62. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-10.
63. Hughes RE, Olson JM. Therapeutic opportunities in polyglutamine disease. Nat Med 2001;7:419-23.
64. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003;54:186-96.
65. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001;8:479-91.
66. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003;421:373-9.
67. Muchowski PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 2002;35:9-12.
68. Seo H, Sonntag KC, Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004;56:319-28.
69. Jana NR, Zemskov EA, Wang G, et al. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001;10:1049-59.
70. Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002;296:2238-43.
71. Hughes RE. Polyglutamine disease: acetyltransferases awry. Curr Biol 2002;12:R141-3.
72. Cattaneo E, Rigamonti D, Goffredo D, et al. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001;24:182-8.